.jpg)
2 hours ago
3
Article content
HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a “going concern” qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley’s Ltd. (here), projected to be completed by July 1, 2026.
Article content
About Impact Biomedical Inc.
Article content
Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Article content
Safe Harbor Statement
This press release contains forward-looking statements. These statements involve risks and uncertainties, including the company’s ability to close its pending merger and secure additional financing to address the going concern doubt expressed by its auditors. Actual results may differ materially.
Article content
Article content
Article content
Article content
Article content
Article content
Article content
Article content
English (US)